small molecule

ORACEA

DOXYCYCLINE

Loss of exclusivityDecember 2027latest FDA-listed patent expiry
CompanyGALDERMA LABORATORIES LP

Drug detail

Brand nameORACEA
Active ingredientDOXYCYCLINE
Strength40MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalMay 2006
Marketing statusRX

Listed patents

PatentExpiresType
7749532December 2027product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ORACEA patent cliff — loss of exclusivity December 2027 | CliffBio